Skip to content

Author

Tetsuya Mitsudomi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN

ABSTRACT In the phase 3 AEGEAN study, perioperative durvalumab plus neoadjuvant chemotherapy significantly improved the primary endpoints of event‐free survival (EFS) and pathological complete response (pCR) in patients with resectable NSCLC versus neoadjuvant chemotherapy alone. We report prespecified exploratory Japa...

Tetsuya Mitsudomi, J. Heymach, Y. Horio et al. · 0 citations
Open access Sep 2026

Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer.

Clinical benefit with perioperative durvalumab plus neoadjuvant chemotherapy plus durvalumab or placebo before surgery followed by adjuvant durvalumab or placebo was generally maintained across the surgery subgroups.

David H. Harpole, J. Heymach, M. Reck et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.